文献速递消化道肿瘤放疗姑息放疗与转移瘤

食管癌寡复发再程放疗的多中心回顾性研究

Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study.
PubMed 文献 · Radiat Oncol · 2017-09-05

本研究回顾性分析了2000至2015年日本五家高容量中心248例食管癌淋巴结寡复发接受放化疗的患者,其中33例接受了再程放疗。再程放疗患者的中位总剂量为60 Gy,3年总生存率为17.9%,中位生存期16.0个月,生存率和局部控制率均显著劣于无既往放疗史者,并有1例治疗相关胃出血死亡。

要点

  • 再程放疗患者3年总生存率17.9%,中位生存16.0个月。
  • 再程放疗患者生存和局控显著劣于无既往放疗史者(p=0.016和p=0.0007)。
  • 再程放疗中位总剂量60 Gy,中位最大淋巴结直径22 mm。

核心结论

  • 对经根治性放疗或手术联合放疗后淋巴结寡复发的食管癌患者,再程放疗可能可接受但疗效不令人满意。

研究设计与样本

  • 多中心回顾性研究,纳入2000至2015年日本五家高容量中心248例食管癌淋巴结寡复发接受放化疗的患者,其中33例接受再程放疗并与其余患者比较。

主要发现

  • 再程放疗患者中位最大淋巴结直径22 mm,中位总剂量60 Gy。
  • 再程放疗患者中位BED10显著低于其他患者。
  • 再程放疗患者中位随访21.7个月,3年总生存率17.9%,中位生存期16.0个月。
  • 再程放疗患者总生存率和局部控制率显著劣于无既往放疗史者(log-rank检验,p=0.016和p=0.0007)。
  • 再程放疗患者中1例死于治疗相关胃出血。

临床怎么用

  • 再程放疗可用于经选择的食管癌淋巴结寡复发患者,但需权衡疗效不佳与治疗相关毒性风险。

局限性

  • 回顾性研究设计,再程放疗组样本量仅33例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemoradiotherapy following surgery has recently become a standard therapy. The purpose of the present study was to determine the effectiveness and toxicity of re-irradiation for oligo-recurrence in lymph nodes from esophageal cancer treated by definitive radiotherapy or by surgery with additional radiotherapy. METHODS: We reviewed retrospectively 248 patients treated with (chemo)radiotherapy for oligo-recurrence in lymph nodes from esophageal cancer in five Japanese high-volume centers between 2000 and 2015. Thirty-three patients in whom re-irradiation was performed were enrolled in this study, and the results for patients in whom re-irradiation was performed were compared with the results for other patients. RESULTS: Median maximum lymph node diameter was 22 mm. Median total radiation dose was 60 Gy. The median calculated biological effective dose using the LQ model with α/β = 10 Gy (BED10) in patients in whom re-irradiation was performed was significantly lower than the median BED10 in others. There was no different factor except for BED10, histology and irradiation field between patients with a past irradiation history and patients without a past irradiation history. The median observation period in surviving patients in whom re-irradiation was performed was 21.7 months. The 3-year overall survival rate in the 33 patients with a past irradiation history was 17.9%, with a median survival period of 16.0 months. Overall survival rate and local control rate in patients with a past irradiation history were significantly worse than those in patients without a past irradiation history (log-rank test, p = 0.016 and p = 0.0007, respectively). One patient in whom re-irradiation was performed died from treatment-related gastric hemorrhage. CONCLUSIONS: Results in the present study suggested that re-irradiation for oligo-recurrence in lymph nodes from esophageal cancer treated by definitive radiotherapy or by surgery with additional radiotherapy might be acceptable but unsatisfactory.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jingu K, Niibe Y, Yamashita H, et al. Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study. Radiat Oncol. 2017. PMID: 28870211. doi:10.1186/s13014-017-0882-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。